CRISPR-modified human iPSC-microglia respond to Alzheimer’s pathology with therapeutic action, opening new avenues for CNS disease treatment.
A team of researchers at the University of California, Irvine, has demonstrated a method for delivering therapeutic proteins to the brain using engineered human microglia derived from induced pluripotent stem cells (iPSCs) [1]. These modified cells act as living drug delivery systems, capable of detecting amyloid plaque build-up – a hallmark of Alzheimer’s disease – and responding by producing an amyloid-degrading enzyme, neprilysin, at the site of pathology.
One of the most significant challenges in treating neurodegenerative diseases has been the blood-brain barrier (BBB), which severely limits the effectiveness of systemic drug delivery. The approach developed by the UC Irvine group circumvents this barrier entirely by transplanting microglia that are already resident in the central nervous system (CNS) and can dynamically respond to disease states [1]. The engineered microglia use the CD9 promoter, a pathology-responsive genetic switch, to activate neprilysin expression only in proximity to amyloid plaques.
Longevity.Technology: Published in Cell Stem Cell, this study demonstrates the potential of engineered human microglia as a dynamic, brain-wide drug delivery platform. By coupling CRISPR-edited iPSC-derived microglia with pathology-responsive promoters, the team has developed a system capable of sensing amyloid plaques and responding with pinpoint delivery of therapeutic enzymes – a feat long sought in Alzheimer’s research. Particularly compelling is the self-regulating nature of the therapy, with neprilysin secretion scaled to disease burden, and its ability to mitigate not only plaque load but also hallmarks of neuroinflammation and synaptic loss – outcomes tightly bound to cognitive decline. This precision targeting may prove key in avoiding the systemic side effects that have hampered previous biologic approaches.
Still, several hurdles remain before clinical translation: durability of effect in humans, large-scale iPSC differentiation and editing, and regulatory paths for live cell CNS therapies. Moreover, while autologous transplantation – using a patient’s own cells – offers a route to immunocompatibility, it rather limits scalability. What is needed next is careful exploration of safety, alternative delivery methods and perhaps expansion to other age-related CNS diseases such as Parkinson’s or MS – areas where this versatile platform shows early promise. As a proof of concept, however, this work significantly expands the toolkit for targeting neurodegeneration in the aging brain, with significant implications for both healthspan and lifespan.
Targeted delivery with CNS-wide impact
To assess efficacy, the researchers used an Alzheimer’s mouse model genetically engineered to allow human microglial engraftment across the brain. These mice exhibited pathology-responsive expression of neprilysin specifically at amyloid plaque sites, resulting in significant reductions in both soluble and insoluble forms of amyloid-beta, including the neurotoxic oligomers most closely associated with synaptic dysfunction [1].
Importantly, therapeutic benefit was not limited to the vicinity of transplanted cells. “Remarkably, we found that placing the microglia in specific brain areas could reduce toxic amyloid levels and other AD-associated neuropathologies throughout the brain,” said Jean Paul Chadarevian, a postdoctoral scholar in the Blurton-Jones lab and first author on the study. “And because the therapeutic protein was only produced in response to amyloid plaques, this approach was highly targeted yet broadly effective [2].”
Further analyses revealed beneficial effects extending to multiple secondary pathologies. Synaptic proteins such as synaptophysin and PSD-95 were preserved, neuroinflammation markers such as GFAP and pro-inflammatory cytokines were reduced, and plasma neurofilament light chain – a circulating biomarker of neuronal damage – declined significantly in treated animals [1].
Platform potential and disease versatility
The study’s design goes beyond Alzheimer’s; the researchers also tested the engineered microglia in mouse models of brain metastasis and demyelination. In these contexts, microglia adopted distinct transcriptional states in response to disease-specific pathology, suggesting that the same delivery platform could be adapted to treat other CNS diseases [1]. The engineered cells showed evidence of responding to tumor-associated or demyelination-specific signals, positioning them as versatile vehicles for precision delivery in diverse neuropathological environments.
As Mathew Blurton-Jones, professor of neurobiology and behavior at UC Irvine and co-corresponding author, explained: “Delivering biologics to the brain has long been a major challenge because of the blood-brain barrier. We’ve developed a programmable, living delivery system that gets around that problem by residing in the brain itself and responding only when and where it’s needed [2].”
In this approach, CRISPR engineering was used to embed therapeutic genes downstream of native promoters, ensuring that proteins such as neprilysin were expressed only under the molecular cues of disease. Unlike viral vectors or continuous biologic infusions, which can provoke immune responses or off-target effects, the microglial system offers the potential for spatial and temporal control of treatment within the CNS.
“This work opens the door to a completely new class of brain therapies,” said Robert Spitale, UC Irvine professor of pharmaceutical sciences and co-corresponding author on the study. “Instead of using synthetic drugs or viral vectors, we’re enlisting the brain’s immune cells as precision delivery vehicles [2].”
From proof to practice
While the findings represent a significant advance in the field of neurodegenerative disease treatment, translation into clinical use will require further work. The immunological and logistical complexities of autologous cell therapy, the potential variability in patient-derived iPSCs, and the long-term safety of genome-edited cells in the brain are all critical questions. Nonetheless, the demonstration that human microglia can be harnessed in vivo to deliver therapeutic payloads selectively and sustainably marks an important step forward in the development of regenerative strategies to extend CNS healthspan.
Future efforts will likely explore expanded applications across other neurodegenerative conditions, refinements to delivery methods, and the possibility of multiplexed interventions. As the field moves from proof-of-concept toward practical application, engineered microglia may play a growing role in shaping the next generation of longevity-focused therapeutics.
[1] https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(25)00099-2
[2] https://news.uci.edu/2025/04/21/engineered-microglia-show-promise-for-treating-alzheimers-other-brain-diseases/
